Xentria Inc. A Leader in Technology and Innovation

CHICAGO--(BUSINESS WIRE)-- Xentria Inc., a biopharmaceutical company focused on developing novel biologics to address unmet clinical needs, ... Xentria, a Chicago, IL-based biotech company, raised $25M in Equity funding. Xentria Inc. has entered into an exclusive license agreement with New York University (NYU) securing Xentria exclusive rights related to the ... Xentria will license its experimental pulmonary sarcoidosis drug to Meitheal Pharmaceuticals in a deal worth up to $680 million. If the FDA approves this application, Xentria will be allowed to begin clinical trials of XTMAB-16. The company expects trials could begin ... Xentria will transfer the XTMAB-16 intellectual property to Meitheal's parent company, King Friend Industry if the royalties pass $600M; Meitheal to get an ... Xellia is a specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening infections. Xentria Inc. received the U.S. Food and Drug Administration's orphan drug designation for its experimental drug XTMAB-16 to treat an ... Xentria will be eligible for potential royalties exceeding $600 million throughout the agreement. ... company, Hong-Kong King Friend Industry Co. Get Kathleen Shanahan's email address (k******@xentria.com) and phone number (773848....) at RocketReach. Get 5 free searches.